Canada hit a milestone on January 4, 2026, when Novo Nordisk's semaglutide patent lapsed. We're the first major Western market where generic semaglutide can be legally manufactured and sold. Brand-name semaglutide runs $260 to $308 per month. Generics are projected at 25 to 40% of that, potentially under $100.
Why Canada and not the US or EU
In the US, EU, and UK, semaglutide patent protection extends into the 2030s. Canada's earlier lapse came down to a patent maintenance fee issue that ended Novo Nordisk's Canadian protection sooner than expected. That timing put Canada uniquely first in line for generic submissions to a national regulator.
What a generic actually is
A generic contains the same active ingredient as the brand-name product at identical doses and formulations. Health Canada requires bioequivalence: the generic has to deliver the same drug into the bloodstream at the same rate. For complex synthetic peptides like semaglutide, the bar is higher. Manufacturers have to prove the molecule folds and behaves identically to the original.
Generics don't repeat full clinical trials. They lean on the brand-name drug's safety and efficacy data, the STEP and SUSTAIN programs in semaglutide's case.
Who's submitting
As of April 2026, nine generic semaglutide submissions from five companies are under Health Canada review:
- Sandoz Canada
- Apotex (three submissions)
- Taro Pharmaceuticals
- Aspen Pharmacare
- Teva Canada
That's an unusually high submission count. It reflects the commercial opening Canada's early patent expiration created.
Timeline
- January 4, 2026. Patent lapsed. Generic submissions became legally permissible.
- Now. Nine submissions under Health Canada review.
- Q3 2026 at earliest. First approvals expected. Health Canada targets a 180-day review window.
- Late 2026 at earliest. Realistic estimate for broad pharmacy availability.
What it'll cost
Under provincial pricing rules, generics typically settle at 25 to 40% of brand-name prices once multiple competitors enter the market.
- Ozempic (0.5 to 1 mg). Brand, diabetes. $260 to $308 per month.
- Wegovy (2.4 mg). Brand, weight management. $380 to $430 per month.
- Generic semaglutide. Estimated $65 to $120 per month post-approval.
One manufacturer publicly indicated a target under $100 per month.
What about coverage
Coverage depends on plan and diagnosis. Alberta Blue Cross and most provincial plans currently cover semaglutide for type 2 diabetes under specific criteria, but not routinely for weight management alone. When generics arrive, coverage rules are expected to mirror existing brand-name policies.
Private employer plans that cover Ozempic for eligible diagnoses will typically switch to the generic version once available. Coverage for weight management remains inconsistent and is unlikely to change with generic introduction.
What about Wegovy, Mounjaro, Zepbound
Unaffected. The patent lapse applies only to semaglutide. Tirzepatide (Mounjaro, Zepbound) has separate patent protection extending to roughly 2036, with formulation patents beyond that. Liraglutide (Saxenda, Victoza) maintains its own patent status. Patients on these alternatives are not affected.
Should I do anything now
For most patients, no immediate action. If semaglutide is working, there's no reason to discontinue or switch while we wait on generics. Supply has stabilised. Stay on your current regimen.
When generics arrive, your pharmacist can advise whether switching makes sense based on your plan coverage, current dose, and which approved generic products are actually available. Not every generic will cover every dose, some may approve for the lower diabetes doses (0.5 to 1 mg) without the higher weight-management doses (1.7 to 2.4 mg).
For out-of-pocket payers, generic arrival could mean meaningful cost reduction.
Don't import from abroad
Buying semaglutide online from other countries carries real risk: counterfeit, substandard, or incorrectly dosed product. Health Canada hasn't approved foreign generics for Canadian use. Get semaglutide through licensed Canadian pharmacies only.
Walk in or call
(780) 443-0202. We'll review your current coverage, walk you through your options, and let you know when an approved generic that matches your dose arrives.